Cargando…

1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome

BACKGROUND: Phase III/IIIb studies demonstrated cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) dosed every 4 weeks (Q4W) was noninferior to current antiviral regimen (CAR) (FLAIR and ATLAS) and CAB + RPV LA dosed every 8 weeks (Q8W) was noninferior to Q4W (ATLAS-2M) through Week 48 (W48). H...

Descripción completa

Detalles Bibliográficos
Autores principales: Talarico, Christine L, Wu, Sterling, Upadhyay, Ojesh R, Clair, Marty St, Van Eygen, Veerle, Hudson, Krischan J, Griffith, Sandy, Harrington, Conn M, van Lunzen, Jan, Margolis, David, Spreen, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777350/
http://dx.doi.org/10.1093/ofid/ofaa439.1207
_version_ 1783630882234433536
author Talarico, Christine L
Wu, Sterling
Upadhyay, Ojesh R
Clair, Marty St
Van Eygen, Veerle
Hudson, Krischan J
Griffith, Sandy
Harrington, Conn M
van Lunzen, Jan
Margolis, David
Spreen, William
author_facet Talarico, Christine L
Wu, Sterling
Upadhyay, Ojesh R
Clair, Marty St
Van Eygen, Veerle
Hudson, Krischan J
Griffith, Sandy
Harrington, Conn M
van Lunzen, Jan
Margolis, David
Spreen, William
author_sort Talarico, Christine L
collection PubMed
description BACKGROUND: Phase III/IIIb studies demonstrated cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) dosed every 4 weeks (Q4W) was noninferior to current antiviral regimen (CAR) (FLAIR and ATLAS) and CAB + RPV LA dosed every 8 weeks (Q8W) was noninferior to Q4W (ATLAS-2M) through Week 48 (W48). HIV-1 ribonucleic acid (RNA) blips (viral load [VL] ≥50 to < 200 c/mL) are common during antiretroviral therapy (ART) and generally not associated with subsequent virologic failure (2 consecutive HIV-1 RNA ≥200 c/mL). We compared the frequency of HIV-1 RNA blips and low-level qualitative and quantitative HIV-1 RNA replication among participants treated with CAB+RPV LA and oral CAR and assessed impact on virologic outcome. METHODS: Plasma samples collected at study visits were analyzed for HIV-1 RNA viral load using the Abbott RealTime HIV-1 assay and qualitative target detected (TD) or target not detected (TND) outcomes were provided for HIV-1 RNA < 40 c/mL. The HIV-1 SuperLow assay (bioMONTR Labs) was used to measure HIV-1 RNA < 2 c/mL at Baseline and W48. RESULTS: The proportion of participants with HIV-1 RNA blips was similar overall between Q4W CAB + RPV LA and CAR arms in FLAIR (38/283 [13%] vs 39/283 [14%]) and ATLAS (17/308 [6%] vs 23/308 [7%]). Presence of HIV-1 RNA blips in either arm was not associated with virologic non-response at W48 (HIV-1 RNA ≥50 c/mL per US Food and Drug Administration Snapshot). In ATLAS-2M, HIV-1 RNA blips were observed in 32/523 (6%; Q4W) and 18/522 (3%; Q8W) of participants, with W48 virologic nonresponse in 2 Q4W and 0 Q8W participants. TD outcomes at individual study visits were comparable between study arms for the 3 studies. At W48, the proportion of participants with HIV-1 RNA < 2 c/mL was similar to Baseline and similar between treatment groups in all studies. CONCLUSION: The proportions of study participants with HIV-1 RNA blips, TD viral load results, and HIV-1 < 2 c/mL were similar between the Q4W and Q8W CAB+RPV LA and the oral 3-drug CAR arms through W48 in phase III/IIIb studies. HIV-1 RNA blips did not predict virologic nonresponse (Snapshot analysis) at W48. DISCLOSURES: Christine L. Talarico, M.S, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Sterling Wu, PhD, GlaxoSmithKline (Employee, Shareholder) Marty St. Clair, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Veerle Van Eygen, MSc, Janssen Pharmaceutica NV (Employee) Krischan J. Hudson, PhD, MPH, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Sandy Griffith, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Conn M. Harrington, BA, ViiV Healthcare (Employee) Jan van Lunzen, MD, PhD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) David Margolis, MD, MPH, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) William Spreen, PharmD, ViiV Healthcare (Employee, Shareholder)
format Online
Article
Text
id pubmed-7777350
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77773502021-01-07 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome Talarico, Christine L Wu, Sterling Upadhyay, Ojesh R Clair, Marty St Van Eygen, Veerle Hudson, Krischan J Griffith, Sandy Harrington, Conn M van Lunzen, Jan Margolis, David Spreen, William Open Forum Infect Dis Poster Abstracts BACKGROUND: Phase III/IIIb studies demonstrated cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) dosed every 4 weeks (Q4W) was noninferior to current antiviral regimen (CAR) (FLAIR and ATLAS) and CAB + RPV LA dosed every 8 weeks (Q8W) was noninferior to Q4W (ATLAS-2M) through Week 48 (W48). HIV-1 ribonucleic acid (RNA) blips (viral load [VL] ≥50 to < 200 c/mL) are common during antiretroviral therapy (ART) and generally not associated with subsequent virologic failure (2 consecutive HIV-1 RNA ≥200 c/mL). We compared the frequency of HIV-1 RNA blips and low-level qualitative and quantitative HIV-1 RNA replication among participants treated with CAB+RPV LA and oral CAR and assessed impact on virologic outcome. METHODS: Plasma samples collected at study visits were analyzed for HIV-1 RNA viral load using the Abbott RealTime HIV-1 assay and qualitative target detected (TD) or target not detected (TND) outcomes were provided for HIV-1 RNA < 40 c/mL. The HIV-1 SuperLow assay (bioMONTR Labs) was used to measure HIV-1 RNA < 2 c/mL at Baseline and W48. RESULTS: The proportion of participants with HIV-1 RNA blips was similar overall between Q4W CAB + RPV LA and CAR arms in FLAIR (38/283 [13%] vs 39/283 [14%]) and ATLAS (17/308 [6%] vs 23/308 [7%]). Presence of HIV-1 RNA blips in either arm was not associated with virologic non-response at W48 (HIV-1 RNA ≥50 c/mL per US Food and Drug Administration Snapshot). In ATLAS-2M, HIV-1 RNA blips were observed in 32/523 (6%; Q4W) and 18/522 (3%; Q8W) of participants, with W48 virologic nonresponse in 2 Q4W and 0 Q8W participants. TD outcomes at individual study visits were comparable between study arms for the 3 studies. At W48, the proportion of participants with HIV-1 RNA < 2 c/mL was similar to Baseline and similar between treatment groups in all studies. CONCLUSION: The proportions of study participants with HIV-1 RNA blips, TD viral load results, and HIV-1 < 2 c/mL were similar between the Q4W and Q8W CAB+RPV LA and the oral 3-drug CAR arms through W48 in phase III/IIIb studies. HIV-1 RNA blips did not predict virologic nonresponse (Snapshot analysis) at W48. DISCLOSURES: Christine L. Talarico, M.S, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Sterling Wu, PhD, GlaxoSmithKline (Employee, Shareholder) Marty St. Clair, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Veerle Van Eygen, MSc, Janssen Pharmaceutica NV (Employee) Krischan J. Hudson, PhD, MPH, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Sandy Griffith, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Conn M. Harrington, BA, ViiV Healthcare (Employee) Jan van Lunzen, MD, PhD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) David Margolis, MD, MPH, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) William Spreen, PharmD, ViiV Healthcare (Employee, Shareholder) Oxford University Press 2020-12-31 /pmc/articles/PMC7777350/ http://dx.doi.org/10.1093/ofid/ofaa439.1207 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Talarico, Christine L
Wu, Sterling
Upadhyay, Ojesh R
Clair, Marty St
Van Eygen, Veerle
Hudson, Krischan J
Griffith, Sandy
Harrington, Conn M
van Lunzen, Jan
Margolis, David
Spreen, William
1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
title 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
title_full 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
title_fullStr 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
title_full_unstemmed 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
title_short 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
title_sort 1021. hiv-1 rna blips and low-level replication during phase iii/iiib cabotegravir + rilpivirine long-acting studies are similar to oral 3-drug therapy and not associated with week 48 virologic outcome
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777350/
http://dx.doi.org/10.1093/ofid/ofaa439.1207
work_keys_str_mv AT talaricochristinel 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT wusterling 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT upadhyayojeshr 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT clairmartyst 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT vaneygenveerle 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT hudsonkrischanj 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT griffithsandy 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT harringtonconnm 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT vanlunzenjan 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT margolisdavid 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome
AT spreenwilliam 1021hiv1rnablipsandlowlevelreplicationduringphaseiiiiiibcabotegravirrilpivirinelongactingstudiesaresimilartooral3drugtherapyandnotassociatedwithweek48virologicoutcome